Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Economic Development | 1 | 2025 | 3 | 0.910 |
Why?
|
| Models, Economic | 1 | 2025 | 62 | 0.870 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 59 | 0.820 |
Why?
|
| Ecology | 1 | 2023 | 82 | 0.760 |
Why?
|
| Seroepidemiologic Studies | 7 | 2024 | 57 | 0.750 |
Why?
|
| India | 7 | 2024 | 138 | 0.700 |
Why?
|
| Poverty Areas | 1 | 2020 | 37 | 0.660 |
Why?
|
| Drug Approval | 2 | 2012 | 69 | 0.620 |
Why?
|
| Research Design | 1 | 2022 | 630 | 0.580 |
Why?
|
| Residence Characteristics | 1 | 2020 | 213 | 0.580 |
Why?
|
| Software | 1 | 2022 | 698 | 0.560 |
Why?
|
| Placebo Effect | 2 | 2008 | 35 | 0.560 |
Why?
|
| Health Status Disparities | 1 | 2020 | 221 | 0.540 |
Why?
|
| Civil Rights | 1 | 2017 | 8 | 0.530 |
Why?
|
| Social Discrimination | 1 | 2017 | 7 | 0.530 |
Why?
|
| Developing Countries | 3 | 2024 | 91 | 0.500 |
Why?
|
| Minority Groups | 1 | 2017 | 154 | 0.480 |
Why?
|
| Biological Evolution | 1 | 2023 | 1030 | 0.460 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1166 | 0.450 |
Why?
|
| Meningitis, Meningococcal | 1 | 2014 | 1 | 0.420 |
Why?
|
| Cetirizine | 1 | 2013 | 12 | 0.410 |
Why?
|
| Television | 1 | 2013 | 29 | 0.400 |
Why?
|
| Loratadine | 1 | 2013 | 21 | 0.400 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 157 | 0.390 |
Why?
|
| Information Dissemination | 1 | 2014 | 126 | 0.390 |
Why?
|
| Global Health | 1 | 2014 | 213 | 0.370 |
Why?
|
| Hypersensitivity | 1 | 2013 | 166 | 0.350 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 492 | 0.350 |
Why?
|
| Vaccination | 4 | 2024 | 311 | 0.350 |
Why?
|
| Legislation, Drug | 1 | 2008 | 7 | 0.290 |
Why?
|
| Humans | 18 | 2025 | 95803 | 0.240 |
Why?
|
| Bayes Theorem | 2 | 2024 | 404 | 0.230 |
Why?
|
| Population Growth | 1 | 2025 | 13 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 348 | 0.220 |
Why?
|
| Hot Temperature | 1 | 2025 | 217 | 0.210 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 74 | 0.200 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 189 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 569 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 163 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2024 | 594 | 0.190 |
Why?
|
| Causality | 1 | 2022 | 84 | 0.190 |
Why?
|
| Peer Group | 1 | 2023 | 94 | 0.190 |
Why?
|
| Sample Size | 1 | 2022 | 128 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 84 | 0.170 |
Why?
|
| Adult | 6 | 2024 | 28582 | 0.160 |
Why?
|
| Exercise | 1 | 2023 | 355 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 147 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2022 | 1158 | 0.140 |
Why?
|
| Young Adult | 4 | 2024 | 7026 | 0.140 |
Why?
|
| Adolescent | 4 | 2024 | 9873 | 0.130 |
Why?
|
| Prevalence | 1 | 2020 | 1349 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 28207 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1879 | 0.120 |
Why?
|
| Child | 3 | 2024 | 7618 | 0.120 |
Why?
|
| United States | 3 | 2017 | 7765 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 640 | 0.110 |
Why?
|
| Meningococcal Vaccines | 1 | 2014 | 4 | 0.110 |
Why?
|
| Public Health | 1 | 2015 | 155 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2015 | 182 | 0.100 |
Why?
|
| Africa | 1 | 2014 | 107 | 0.100 |
Why?
|
| International Cooperation | 1 | 2014 | 134 | 0.100 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2013 | 15 | 0.100 |
Why?
|
| World Health Organization | 1 | 2014 | 122 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2014 | 218 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 468 | 0.090 |
Why?
|
| Aged | 3 | 2024 | 20848 | 0.080 |
Why?
|
| Male | 4 | 2021 | 45686 | 0.080 |
Why?
|
| Fraud | 1 | 2008 | 6 | 0.070 |
Why?
|
| Consumer Advocacy | 1 | 2008 | 10 | 0.070 |
Why?
|
| Liability, Legal | 1 | 2008 | 29 | 0.070 |
Why?
|
| Female | 4 | 2021 | 49872 | 0.070 |
Why?
|
| Malpractice | 1 | 2008 | 57 | 0.070 |
Why?
|
| Bias | 1 | 2008 | 139 | 0.070 |
Why?
|
| Caffeine | 1 | 2008 | 85 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 397 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 500 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3904 | 0.060 |
Why?
|
| Informed Consent | 1 | 2008 | 281 | 0.060 |
Why?
|
| Heart Rate | 1 | 2008 | 518 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 235 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2008 | 435 | 0.050 |
Why?
|
| Time Factors | 1 | 2013 | 5561 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 926 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2023 | 38 | 0.050 |
Why?
|
| Public Policy | 1 | 2022 | 61 | 0.040 |
Why?
|
| Rural Health | 1 | 2021 | 18 | 0.040 |
Why?
|
| Urban Health | 1 | 2021 | 55 | 0.040 |
Why?
|
| Health Surveys | 1 | 2021 | 245 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2013 | 9167 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 380 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1957 | 0.040 |
Why?
|
| Pandemics | 1 | 2024 | 880 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 491 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2024 | 3970 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7215 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 208 | 0.030 |
Why?
|